截至2026年1月30日收盘，惠博普(002554)报收于4.13元，下跌6.14%，换手率10.77%，成交量143.67万 手，成交额6.03亿元。 当日关注点 公司公告汇总 华油惠博普科技股份有限公司预计2025年度归属于上市公司股东的净利润亏损15,000万元至20,000万 元，上年同期亏损19,098.33万元；扣除非经常性损益后的净利润亏损16,800万元至21,800万元。业绩亏 损主要原因系汇率波动导致汇兑损失增加，对墨西哥天然气发电项目仲裁事项预提损失，以及计提长期 股权投资等资产减值准备。本次业绩预告未经会计师事务所审计，最终数据以2025年年度报告为准。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 来自交易信息汇总：1月30日惠博普收盘报4.13元，跌6.14%，主力资金当日净流出3796.31万元。 来自业绩披露要点：惠博普预计2025年全年归属净利润亏损1.5亿元至2亿元，扣非后净利润亏损 1.68亿元至2.18亿元。 来自公司公告汇总：业绩亏损主因包括汇率波动导致汇兑损失增加、对墨西哥天然气发电项目 ...

Core Viewpoint - ST Er Ya (600107) is facing significant financial challenges, with projected losses for 2025 and potential delisting risks due to non-compliance with financial reporting standards [1][2][3] Financial Performance Summary - ST Er Ya expects a net profit loss of between 90 million to 135 million yuan for the year 2025, with a non-recurring net profit loss estimated between 100 million to 150 million yuan [1][3] - The anticipated total revenue for 2025 is projected to be between 210 million to 260 million yuan, with revenue from core operations expected to be between 207 million to 257 million yuan [1] Company Announcements - The company and its actual controller, Zheng Jiping, have been penalized by the Hubei Securities Regulatory Bureau for information disclosure violations, involving a total of 10.372 million yuan in non-operating fund occupation [2][3] - The company’s stock may face delisting risk warnings following the 2025 annual report if the audited financial indicators remain negative and revenue falls below 300 million yuan [1][2][3] - ST Er Ya has sold 100% equity of Genuo Energy and Jianqin Energy for 18 million yuan, receiving 9.18 million yuan so far, with the transaction expected to generate a profit of approximately 8.16 million yuan [2][3]

截至2026年1月30日收盘，硕世生物（688399）报收于71.92元，较上周的78.71元下跌8.63%。本周，硕 世生物1月26日盘中最高价报94.0元，股价触及近一年最高点。1月30日盘中最低价报71.3元。硕世生物 当前最新总市值60.32亿元，在医疗器械板块市值排名60/127，在两市A股市值排名3047/5184。 本周关注点 业绩披露要点 公司公告汇总 江苏硕世生物科技股份有限公司预计2025年度实现归属于母公司所有者的净利润为-2,940万元到-4,400 万元，与上年同期相比扩大亏损2,739.83万元到4,199.83万元；扣除非经常性损益后的净利润为-8,190万 元到-12,280万元，亏损同比扩大1,006.29万元到5,096.29万元。业绩亏损主要受行业竞争加剧、医疗集 采推进、自产检测试剂增值税税率调整、政府补助减少及资产减值准备计提等因素影响。本次业绩预告 未经审计。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 业绩披露要点：硕世生物预计2025年归属净利润亏损2940万元至4400万元。 业 ...

Core Viewpoint - Xiwang Food is expected to report a significant increase in losses for the fiscal year 2025, with projected net losses ranging from 880 million to 1.32 billion yuan, compared to a loss of 444 million yuan in the previous year, indicating a year-on-year doubling of losses [1][2]. Financial Performance - The company anticipates a net profit attributable to shareholders of a loss between 880 million and 1.32 billion yuan for 2025, compared to a loss of 443.57 million yuan in the same period last year [2]. - The expected net profit after deducting non-recurring gains and losses is projected to be a loss between 880 million and 1.3 billion yuan, compared to a loss of 432.73 million yuan in the previous year [2]. - Basic earnings per share are expected to be between -1.22 yuan and -0.82 yuan, compared to -0.41 yuan per share last year [2]. - The company has reported consecutive losses over the past three years, with cumulative losses amounting to approximately 1.08 billion yuan from 2022 to 2024 [2]. Operational Challenges - The increase in losses is attributed to rising prices of raw materials, particularly whey protein, and intensified competition in the sports nutrition sector [2]. - The company plans to recognize an impairment loss on intangible assets estimated between 950 million and 1.5 billion yuan, subject to final audit [2]. Strategic Outlook - Despite the challenges, the management aims to implement significant corrective measures in 2026 to improve future performance [4]. - The company plans to optimize product costs by diversifying its product portfolio, shifting towards high-margin products, and reducing reliance on whey protein [4]. - Xiwang Food intends to expand into new product categories, including new proteins, creatine, peptides, and collagen, to build a strong innovative product line [4]. Market and Cost Management - The company will increase investment in digital channels, focusing on high-margin categories through platforms like Amazon, while optimizing product offerings at Walmart [5]. - A strict cost control policy will be adopted, including dynamic budget monitoring, expenditure reduction, and optimization of organizational structure to enhance operational efficiency [5]. - As of January 30, the company's stock price decreased by 1.25% to 3.17 yuan per share, with a total market capitalization of approximately 3.422 billion yuan, indicating stagnant stock performance over the past year [5].

1月30日，闻泰科技发布2025年业绩预告，公司全年业绩出现大幅亏损，核心系子公司安世半导体相关 控制权受限引发连锁反应，具体业绩数据如下： 业绩数据方面，2025年公司归属于母公司所有者的净利润预计为-135亿元至-90亿元，扣除非经常性损 益后的净利润预计为-3亿元至-2亿元。对比上年同期数据，公司此前利润总额为-19.11亿元，归属于母 公司所有者的净利润为-28.33亿元，扣非后归母净利润为-32.42亿元，每股收益为-2.28元/股，可见本期 亏损规模显著扩大，核心差异源于非经常性损益相关的投资及资产减值损失。 | | | 业绩变动的核心诱因是子公司安世的控制权受限问题，该事项不仅直接影响公司对核心资产的管 控，更对整体经营及业绩核算造成根本性冲击。 2025年第四季度，闻泰科技核心子公司安世半导体有限公司与安世半导体控股有限公司（合称"安 世"），先后收到荷兰经济事务与气候政策部下达的部长令（Order）及阿姆斯特丹上诉法院企业法 庭的裁决。截至本报告期末，虽经公司推动，上述荷兰经济事务与气候政策部的部长令已被宣布暂 停执行，但阿姆斯特丹上诉法院企业法庭的裁决仍处于生效状态，这一法律层面的生效裁决 ...

万科方面表示，将全力以赴推进经营改善，通过战略聚焦、规范运作和科技赋能等措施，推动业务布局 优化和结构调整，提升多场景的开发和经营能力，上下凝心聚力，有序地化解风险，摆脱困境，推动公 司早日走出低谷。 封面图片来源：孔泽思 对于2025年业绩亏损的原因，万科在公告中表示，一是房地产开发项目结算规模显著下降，毛利率仍处 低位。2025年房地产开发业务结算利润主要对应2023年、2024年销售的项目及2025年消化的现房和准现 房库存，这些项目的地价获取成本较高，导致报告期结算毛利总额大幅减少；二是因业务风险敞口升 高，新增计提了信用减值和资产减值；三是部分经营性业务扣除折旧摊销后整体亏损，以及部分非主业 财务投资亏损；四是部分大宗资产交易和股权交易价格低于账面值。 过去一年，万科面临多重艰巨挑战，在大股东和各方的大力支持下，万科全力以赴、攻坚克难，实现了 殊为不易的生产经营稳定。 尽管各方大力支持，企业也全力行动，但受多重因素影响，万科经营业绩仍高度承压，历史包袱十分沉 重。 2025年，大股东深圳地铁集团竭尽所能提供了多种形式支持，帮助万科维持生产经营稳定。根据公开信 息，深铁累计向万科提供了超300亿元的股 ...

Core Viewpoint - Haocen Medical is expected to report a net profit loss of 65 million to 130 million yuan for the entire year of 2025 due to increased market competition and rising customer acquisition costs in the dental medical service sector [1][2]. Financial Performance Summary - For the first three quarters of 2025, the company's main revenue was 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders was -26.41 million yuan, a year-on-year decline of 295.68% [2]. - The net profit after deducting non-recurring gains and losses was -24.52 million yuan, down 288.77% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 213 million yuan, a decrease of 15.72% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -2.66 million yuan, a decline of 120.54% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was -0.97 million yuan, down 107.53% year-on-year [2]. - The company's debt ratio stood at 71.72%, with investment income of 2.67 million yuan and financial expenses of 31.15 million yuan [2]. - The gross profit margin was 47.72% [2]. Reasons for Performance Change - The decline in performance is attributed to intensified market competition, increased customer acquisition costs, and a significant drop in average customer spending in the dental medical service sector [2]. - The company plans to recognize goodwill impairment and long-term equity investment impairment based on cautious principles due to the expected recoverable amounts being lower than their book values [2].

Core Viewpoint - Haocen Medical is expected to report a loss per share of between 0.0833 yuan and 0.1666 yuan for the full year of 2025, primarily due to increased market competition and rising customer acquisition costs in the dental medical service sector [1][2]. Financial Performance - For the first three quarters of 2025, the company's main revenue was 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders was -26.41 million yuan, a year-on-year decline of 295.68% [2]. - The net profit after deducting non-recurring items was -24.52 million yuan, down 288.77% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 213 million yuan, a year-on-year decrease of 15.72% [2]. - The single-quarter net profit attributable to shareholders was -2.66 million yuan, a decline of 120.54% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -966,000 yuan, down 107.53% year-on-year [2]. Cost and Profitability - The company faced significant declines in profitability due to a substantial drop in comprehensive customer unit price [2]. - The debt ratio stood at 71.72%, indicating a high level of financial leverage [2]. - The gross profit margin was reported at 47.72%, reflecting the company's ability to maintain some level of profitability despite revenue declines [2]. Impairment and Valuation - The company plans to recognize goodwill impairment based on a cautious principle, following a goodwill impairment test [2]. - Additionally, the company will conduct impairment tests on long-term equity investments, expecting that the recoverable amounts of some investments will be lower than their book values, leading to further impairment provisions [2].

Core Viewpoint - Xiwang Food is forecasting a loss in earnings per share for 2025, estimating a range between -0.82 to -1.22 RMB due to rising raw material costs and increased competition in the sports nutrition sector [1] Group 1: Performance Forecast - The primary reason for the expected performance decline in 2025 is the continuous increase in the price of whey protein and intensifying competitive pressure, leading to underperformance in the sports nutrition segment [1] - The company anticipates recognizing an impairment loss on intangible assets between 950 million to 1.5 billion RMB, subject to final audit by a qualified auditing firm [1] Group 2: Management Strategies for 2026 - In response to challenges, the management plans to implement extensive corrective measures to lay the groundwork for future performance improvement [2] - The company aims to optimize product costs by diversifying its product portfolio, shifting towards high-margin products, and reducing reliance on whey protein [2] - There will be increased investment in digital channels, with Amazon identified as a core growth engine focusing on high-margin categories, while Walmart will optimize its product mix [2] - A strict cost control principle will be adopted, establishing a dynamic budget monitoring mechanism to streamline expenditures and enhance operational efficiency [2] Group 3: Financial Performance - For the first three quarters of 2025, the company reported a main revenue of 3.507 billion RMB, a year-on-year decrease of 8.04% [3] - The net profit attributable to shareholders was 2.2219 million RMB, down 96.45% year-on-year, while the net profit excluding non-recurring items was 7.121 million RMB, a decline of 90.48% [3] - In Q3 2025, the company achieved a single-quarter main revenue of 1.389 billion RMB, an increase of 7.05% year-on-year, but the net profit attributable to shareholders decreased by 5.22% [3] - The company reported a debt ratio of 45.23%, investment income of 4.6342 million RMB, financial expenses of 102 million RMB, and a gross margin of 22.04% [3]

康佳集团公告称，2025年预计营收9-105亿元，较上年的111.15亿元有所下滑；归属于上市公司股东的 净利润亏损125.81-155.73亿元，上年亏损32.96亿元；期末净资产预计为-53.34至-80.01亿元，上年末为 23.70亿元。业绩变动主因是计提减值准备及确认预计负债大幅增加，且消费电子业务受产品竞争力不 足影响，营收下滑且仍处亏损状态。若经审计后2025年末净资产为负，公司股票交易将被实施退市风险 警示。 ...